The Body Keeps the Calendar

Two days before her period, Sarah cancels dinner. She already knows. Not from the cramp — that comes later — but from the shadow behind her right eye, the slow thickening of light into something hostile. By morning, she will be in bed with the curtains drawn, a washcloth on her forehead, hours lost.

She has lived this rhythm for fourteen years.

Sarah is not unusual. Nearly 50% of women with migraine report a connection between their attacks and their menstrual cycle.^[1] Among them, a significant proportion experience what neurologists classify as menstrual migraine — attacks striking within a precise five-day window, from two days before menstruation to three days into bleeding, in at least two out of three consecutive cycles.^[2] These are not ordinary migraines that happen to coincide with a period. They last longer. They hit harder. They resist the medications that work at other times of the month. And they are more likely to return after initial relief.^[3]

Yet no drug on Earth carries an FDA-approved indication specifically for menstrual migraine.^[4]

How is that possible?

The Cliff

The answer begins with a discovery made in 1972 by an Australian neurologist named Brian Somerville. His experiment was deceptively simple: inject estradiol into women who reliably developed migraines before their periods, then observe.^[5]

The migraines vanished — temporarily. They reappeared days later, precisely when the injected estrogen wore off and levels plummeted. The attacks didn't follow the period. They followed the fall.

Somerville's work established what scientists now call the estrogen withdrawal hypothesis, and more than fifty years of subsequent research has confirmed its central claim.^[6] The trigger is not low estrogen itself. It is the speed of the decline. The steeper the drop, the harder the crash.

In 2016, a landmark study within the SWAN cohort — a multiethnic, prospective study tracking 3,302 women through midlife — measured this directly.^[7] Researchers collected daily urinary hormone samples and matched them against headache diaries. The finding was striking: women with migraine showed a 46% greater rate of estrogen decline in the two days after their luteal peak compared with controls (p = 0.002).^[7] The migraine brain doesn't merely experience the hormonal drop. It falls faster and farther.

Dr. Anne MacGregor, whose research led to the International Headache Society's diagnostic criteria for menstrual migraine, demonstrated the same pattern across three consecutive menstrual cycles using daily urinary assays.^[8] Migraine incidence climbed specifically during the phase of falling estrogen. Rising estrogen appeared protective. The women who blamed their hormones were right.

The Cascade

If estrogen withdrawal were the whole story, the solution would be simple: stabilize hormones, stop migraines. But biology rarely cooperates. When estrogen drops, it triggers not one disruption but three — each amplifying the others.

Serotonin crashes. Estrogen directly regulates serotonin synthesis. When estrogen declines, serotonin production slows. Simultaneously, the enzyme that destroys serotonin — monoamine oxidase — accelerates.^[9] Less being made; more being destroyed. This dual collapse may explain why triptans, which depend on serotonin receptors, often underperform against menstrual attacks: the very receptors they target become desensitized when estrogen runs low.^[10]

The brain's painkillers go offline. During the late luteal phase, the capacity to activate μ-opioid receptors — the same system targeted by morphine — becomes impaired.^[11] Pain signals that would normally be dampened arrive at full volume.

Prostaglandins flood the system. Here menstrual migraine diverges most sharply from ordinary migraine. During the first 48 hours of menstruation, the uterus releases prostaglandin E2 — and these molecules don't stay local. Prostaglandin levels can triple between the follicular and menstrual phases.^[10] PGE2 provokes the release of calcitonin gene-related peptide (CGRP) from trigeminal nerve fibers, dilating blood vessels and igniting neurogenic inflammation in the meninges.^[12] Animal models confirm that PGE2 concentrations in pain-processing brain regions rise specifically during periods of low sex hormones, directly increasing CGRP expression.^[12]

MacGregor identified these as two completely independent triggers.^[13] A woman may be vulnerable to the hormonal drop, to the prostaglandin surge, or to both. This explains a clinical puzzle: why some treatments work for some women and fail for others. The triggers differ. So must the strategy.

The Natural Experiments

Science often depends on controlled conditions. Nature, occasionally, provides them for free.

Pregnancy. During the second and third trimesters, estrogen rises steadily — no cliffs, no crashes. About 50% of women with migraine improve by the end of the first trimester. By the second, that figure reaches 80%.^[14] Women with menstrual migraine without aura benefit the most. This isn't correlation. It's a direct test of the estrogen-stability hypothesis.

Perimenopause. The opposite experiment. As ovarian function becomes erratic, estrogen spikes and crashes more dramatically than during any normal cycle. The SWAN study found that women with migraine history experienced significantly higher frequency of headache during the late perimenopausal period (31%) compared with premenopausal controls (16.7%) in a cross-sectional analysis of 1,436 women.^[15] The American Migraine Prevalence and Prevention Study (n = 3,664 women with migraine) confirmed the association: perimenopause and menopause significantly increased the risk of high-frequency headache, defined as more than ten days per month.^[16]

Menopause. Once estrogen finally stabilizes — even at persistently low levels — approximately two-thirds of women with spontaneous menopause see significant improvement.^[17] But women who undergo surgical menopause, with its abrupt hormonal plunge, see migraines worsen in two-thirds of cases.^[17]

The Evidence

Understanding the mechanism is necessary. It is not sufficient. What follows is what the clinical trial data actually support — organized from simplest intervention to most targeted, with sample sizes and effect sizes included.

Three months of tracking comes first. The International Headache Society requires documentation across at least two of three consecutive cycles for diagnosis.^[2] Research confirms that self-reported menstrual migraine is frequently overdiagnosed without prospective diaries.^[3] A dual diary — migraine days alongside menstrual days — remains the diagnostic foundation.

Timed NSAIDs. A double-blind, placebo-controlled trial by Sances and colleagues (n = 34) demonstrated that naproxen sodium (550 mg twice daily), started two days before expected menstruation and continued through day three of bleeding, significantly reduced headache frequency, severity, and duration compared with placebo.^[18] The mechanism is direct: naproxen inhibits cyclooxygenase, blocking the prostaglandin surge that triggers CGRP release.^[4] For women whose migraines travel with painful or heavy periods — a sign of elevated prostaglandin production — this approach does double duty.

Magnesium from cycle day 15. A double-blind, placebo-controlled trial by Facchinetti and colleagues (n = 20) found that 360 mg of oral magnesium daily, begun on day 15 of the cycle and continued until the next period, significantly reduced both menstrual migraine attacks and premenstrual symptoms.^[19] Critically, intracellular magnesium levels were measurably lower in migraine patients at baseline and rose significantly with supplementation, suggesting a direct physiological correction rather than a placebo effect.^[19] Magnesium glycinate is gentler on the stomach; magnesium citrate works better if constipation is a concern.

Vitamin E mini-course. A randomized, double-blind, placebo-controlled trial found that 400 IU of vitamin E daily for five days — starting two days before menstruation and continuing three days after — significantly reduced pain intensity, functional disability, and associated symptoms including photophobia and phonophobia.^[20]

Frovatriptan mini-prevention. The largest and most rigorous trial data exist for this approach. Silberstein and colleagues randomized 546 women in a double-blind, placebo-controlled, three-way crossover design.^[21] Each participant treated three perimenstrual periods with placebo, frovatriptan 2.5 mg once daily, or frovatriptan 2.5 mg twice daily, starting two days before anticipated migraine and continuing for six days. The results: menstrual migraine occurred during 67% of placebo periods, 52% of once-daily periods, and 41% of twice-daily periods (p < 0.0001 for both doses versus placebo). Both regimens also significantly reduced migraine severity, duration, and rescue medication use.^[21] A second trial specifically targeting women with treatment-resistant menstrual migraine (n = 410) confirmed these findings, with the twice-daily regimen doubling the number of headache-free perimenstrual periods compared with placebo (p < 0.001).^[22] A meta-analysis of six randomized controlled trials totaling over 2,800 participants established frovatriptan 2.5 mg twice daily as the most effective triptan for menstrual migraine prevention (RR 1.98, 95% CI 1.68–2.34 versus placebo).^[23]

Hormonal stabilization. Estrogen supplementation — via transdermal patch, gel, or continuous low-dose oral contraceptives without placebo breaks — attacks the root mechanism by preventing the estrogen cliff.^[24] MacGregor's research demonstrated that eliminating or shortening the hormone-free interval can substantially reduce menstrual attacks.^[8] This path requires careful individualized assessment, particularly for women with migraine with aura, in whom estrogen-containing contraceptives carry elevated cardiovascular risk.^[4]

CGRP-targeting therapies. These represent the most significant advance in migraine treatment in decades — and recent evidence confirms their relevance to menstrual migraine specifically. The STRIVE trial (n = 955), published in the New England Journal of Medicine, demonstrated that erenumab — a monoclonal antibody targeting the CGRP receptor — reduced monthly migraine days by approximately 3.7 days at the 140 mg dose, with 50% of patients achieving at least a 50% reduction in migraine frequency versus 26.6% on placebo.^[25] A 2024 meta-analysis of 26 randomized controlled trials confirmed that both erenumab and galcanezumab significantly outperformed triptans in reducing monthly headache days when used as preventive therapy for menstrual migraine, with mean reductions of 2.1 and 2.4 days respectively.^[26] Real-world data from Italian headache centers showed that CGRP monoclonal antibodies reduced menstrual migraine days from five to two per cycle, cut mean attack duration from 24 to 8 hours, and improved acute medication response rates from 42.5% to 95%.^[27]

The Key Question

Menstrual migraine is not a vague complaint. It is a distinct neurobiological event — measurable in hormone assays, visible in CGRP concentrations, and increasingly treatable with therapies designed around its specific mechanisms. A 2024 meta-analysis pooling data from more than 9,100 participants across 16 randomized controlled trials of CGRP monoclonal antibodies confirmed that this class of drugs offers significant, reproducible migraine reduction with a favorable safety profile.^[28]

The most important step isn't any single medication. It is recognizing the pattern. Three months of tracking can separate menstrual migraine from its look-alikes, unlock treatments that non-menstrual strategies miss, and give you a conversation with your doctor rooted in data rather than frustration.